---
document_datetime: 2025-11-24 13:49:56
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: opdualag-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0982331
conversion_datetime: 2025-12-17 09:20:04.615094
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Opdualag

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 24/11/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000309804                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.1.11.z. - to revise the due dates for the milestones related to the voluntarily PASS Category 3 Study, CA224122 'Long-term follow-up of paediatric patients exposed to nivolumab + relatlimab FDC in the DMTR', listed in the Risk Management Plan (RMP). The final due date has been changed from '4Q2038' to '1Q2041'.                                                                                                                          |            |     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000278726 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z - To update section 2.7 of the RMP to reflect Myasthenia gravis for nivolumab + relatlimab FDC as an Important identified risk under Other irARs, following a PRAC assessment of Myasthenia gravis during EMEA/H/C/PSUSA/00011018/202409 (reporting period: 18-Mar-2024 to 17-Sep- 2024, CHMP Opinion date on 25 April 2025). Additionally, the MAH has taken the opportunity to update the following: - Part II | 11/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                          | - Update of Section 2.5 Post Authorisation Experience to align with the exposure section from the PSUR#5. - Part V - Update of Table 5.1 to include reference to the Package Leaflet in 'Routine risk minimisation measures' for embryofetal toxicity for completeness. - Annex 3: Update of Part A to 'None'.                                                                                                                                                                                                  |            |     |             |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA_IN / EMA/VR/0000272593 | B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted                                                                                                                                                                                                                                                                                                                                  | 15/05/2025 | N/A |             |
| Variation type IB / EMA/VR/0000257355    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted | 30/04/2025 | N/A |             |
| PSUR / EMA/PSUR/0000274454               | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     | Maintenance |